ArticleCell death & disease2025
TRIM31 triggers colorectal carcinogenesis and progression by maintaining YBX1 protein stability through ubiquitination modification.
Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- TRIM24 stabilizes the p110 CUX1 oncoprotein via USP10 to promote chemoresistance in acute myeloid leukemia.Journal of translational medicine · 2026Article
- USP22 deubiquitinates and stabilizes ERK1/2 to promote colorectal cancer progression.Acta pharmacologica Sinica · 2026Article
- Genetic Determinants of Microvascular Complications of Type 1 Diabetes Mellitus: New Data from a Replication Study.Biomedicines · 2026Article
- RNA methylation in cardiovascular remodeling: Molecular mechanisms, biomarkers, and therapeutic strategies.Molecular biology reports · 2026Review
- mBiology direct · 2026Review
- TRIM31 inhibits ferroptosis in LUAD through facilitating ubiquitination and degradation of P53.Scientific reports · 2026Article
- Article
- Review
- Bidirectional regulation of the ubiquitin-RNA modification axis in cancer.Frontiers in oncology · 2026Review
- YBX1 as an adaptive RNA hub in cancer: linking state-dependent RNA regulation to tumor immunity, metabolic reprogramming, and therapy resistance.Frontiers in immunology · 2026Review
- Integrative single-cell analysis revealsFrontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Colorectal cancer (CRC) is one of the most common gastrointestinal tumors, and one of the leading causes of cancer-related deaths worldwide. However, the molecular mechanisms underlying CRC development and progression have not been fully elucidated until now. Emerging studies have shown that post-translational modifications of proteins, especially ubiquitination modifications, play an important role in tumorigenesis and progression. Here we identified that the E3 ligase TRIM31, a member of the TRIM (Tripartite Motif) family proteins, is highly expressed during colorectal inflammation-cancer transformation and is associated with poor prognosis in CRC patients. Knockdown of TRIM31 expression led to the suppression of CRC cell proliferation and migration in vitro, tumor formation and metastatic ability in vivo. TRIM31 interacts with YBX1 and catalyses the Lys63 (K63) linkage polyubiquitination of Lys81 on YBX1, which ultimately leads to the stabilization of the YBX1 protein. YBX1 further enhances the stabilization of mRNAs for EREG, GAS6, and MAFG through both m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.